` DESN (Dottikon Es Holding AG) vs Swiss Market Index Comparison - Alpha Spread

DESN
vs
S
Swiss Market Index

Over the past 12 months, DESN has significantly outperformed Swiss Market Index, delivering a return of +73% compared to the Swiss Market Index's +8% growth.

Stocks Performance
DESN vs Swiss Market Index

Loading
DESN
Swiss Market Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
DESN vs Swiss Market Index

Performance Gap Between DESN and SSMI
HIDDEN
Show

Performance By Year
DESN vs Swiss Market Index

Loading
DESN
Swiss Market Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Dottikon Es Holding AG vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Dottikon Es Holding AG
Glance View

Market Cap
5.2B CHF
Industry
Chemicals

Dottikon Es Holding AG stands as one of Switzerland's understated gems in the realm of fine chemicals and pharmaceuticals. Born from Switzerland's rich tradition of precision and quality, the company operates primarily in the realm of exclusive synthesis, tailored to meet the stringent demands of the pharmaceuticals industry. At its core, Dottikon specializes in hazardous chemical reactions, priding itself on an ability to transform complex chemical processes into high-quality results. This specialization provides a competitive edge, allowing Dottikon to focus on developing innovative and complex molecules which serve as active pharmaceutical ingredients (APIs). It's a business model that not only underscores the company's technical expertise but also its commitment to safety and environmental stewardship, given the heightened risks associated with hazardous materials. Revenue for Dottikon is chiefly generated from strategic partnerships with major pharmaceutical companies. By offering a unique combination of research and development capabilities coupled with state-of-the-art production facilities, Dottikon caters to bespoke needs, from initial developmental scales to full-fledged commercial production runs. The trust and collaboration between Dottikon and its clients are pivotal, as the company becomes an indispensable partner in the clients’ supply chain. As the pharmaceutical sector continues to evolve and demand for specialized molecules increases, Dottikon’s focus on exclusivity and expertise positions it well within the industry, ensuring steady demand and solidifying its role as a reliable, albeit lesser-known, catalyst in advancing pharmaceutical innovations.

DESN Intrinsic Value
HIDDEN
Show
Back to Top